Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$1.1 million.

  • Insight Molecular Diagnostics' Cash from Investing Activities fell 1106.90% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 862.81%. This contributed to the annual value of -$512,000 for FY2024, which is 45.06% up from last year.
  • Insight Molecular Diagnostics' Cash from Investing Activities amounted to -$1.1 million in Q3 2025, which was down 200.86% from -$349,000 recorded in Q2 2025.
  • Insight Molecular Diagnostics' Cash from Investing Activities' 5-year high stood at $214,000 during Q3 2023, with a 5-year trough of -$8.3 million in Q1 2021.
  • For the 3-year period, Insight Molecular Diagnostics' Cash from Investing Activities averaged around -$286,364, with its median value being -$191,000 (2024).
  • Per our database at Business Quant, Insight Molecular Diagnostics' Cash from Investing Activities soared by 124.91% in 2023 and then slumped by 1,179.17% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Cash from Investing Activities (Quarterly) stood at -$401,000 in 2021, then crashed by 100.00% to -$802,000 in 2022, then surged by 112.84% to $103,000 in 2023, then tumbled by 303.88% to -$210,000 in 2024, then crashed by 1,106.90% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$349,000 for Q2 2025, and -$307,000 during Q1 2025.